337 related articles for article (PubMed ID: 23922463)
1. Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.
Suppiah A; Greenman J
World J Gastroenterol; 2013 Aug; 19(29):4651-70. PubMed ID: 23922463
[TBL] [Abstract][Full Text] [Related]
2. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
3. [Serum p53 antibody assay: evaluation in colorectal cancer].
Hammel P; Soussi T
Rev Med Interne; 2000 Feb; 21(2):167-73. PubMed ID: 10703073
[TBL] [Abstract][Full Text] [Related]
4. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
Regidor PA; Regidor M; Callies R; Schindler AE
Eur J Gynaecol Oncol; 1996; 17(3):192-9. PubMed ID: 8780917
[TBL] [Abstract][Full Text] [Related]
5. [Value of serum P53 antibody as a tumor marker surveillance of colorectal cancer within follow-up after curative resection].
Shou CC; Huang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Oct; 15(10):1020-2. PubMed ID: 23297459
[TBL] [Abstract][Full Text] [Related]
6. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.
Suppiah A; Alabi A; Madden L; Hartley JE; Monson JR; Greenman J
Int J Colorectal Dis; 2008 Jun; 23(6):595-600. PubMed ID: 18330580
[TBL] [Abstract][Full Text] [Related]
7. Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer.
Teras LR; Gapstur SM; Maliniak ML; Jacobs EJ; Gansler T; Michel A; Pawlita M; Waterboer T; Campbell PT
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):219-223. PubMed ID: 29254936
[No Abstract] [Full Text] [Related]
8. Anti-p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta-analysis.
Liu S; Tan Q; Song Y; Shi Y; Han X
Scand J Immunol; 2020 Feb; 91(2):e12829. PubMed ID: 31536647
[TBL] [Abstract][Full Text] [Related]
9. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis.
Sobhani N; Roviello G; D'Angelo A; Roudi R; Neeli PK; Generali D
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684792
[No Abstract] [Full Text] [Related]
10. Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Nozawa H; Ishihara S; Kawai K; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Watanabe T
Oncology; 2016; 91(3):127-34. PubMed ID: 27362767
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
12. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
[TBL] [Abstract][Full Text] [Related]
14. Serum p53 auto-antibodies: incidence in familial breast cancer.
Green JA; Mudenda B; Jenkins J; Leinster SJ; Tarunina M; Green B; Robertson L
Eur J Cancer; 1994; 30A(5):580-4. PubMed ID: 8080669
[TBL] [Abstract][Full Text] [Related]
15. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer.
Angelopoulou K; Diamandis EP
Eur J Cancer; 1997 Jan; 33(1):115-21. PubMed ID: 9071910
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Ootani K; Yasuda K; Murono K; Watanabe T
Oncology; 2017; 92(1):31-38. PubMed ID: 27794579
[TBL] [Abstract][Full Text] [Related]
17. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.
Daitoku N; Miyamoto Y; Sakamoto Y; Tokunaga R; Hiyoshi Y; Nagai Y; Iwatsuki M; Iwagami S; Yoshida N; Baba H
Int J Clin Oncol; 2020 Apr; 25(4):651-659. PubMed ID: 31834556
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Iwasaki K; Makino H; Natsume T; Kouno T; Kondo S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):879-83. PubMed ID: 10897215
[TBL] [Abstract][Full Text] [Related]
20. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
